So that was my last role as an academic cat herder,
so I spent the last 10 years trying to get clinicians and academics talking to each other inside Oxford.
And now I'm working on trying to get different disciplines working together
across the UK through the National Consortium of Intelligent Medical Imaging.
As Mike says, it's one of the initiatives we're working around.
The ethics of the use of image data and medical imaging and See Me involves 15 hospital trusts across the length and breadth of the UK,
nine industry partners. So we've got a particular interest in the use of patient and health data by companies,
by small and international global players and of spread across cancer, cardiovascular medicine, metabolic health, stroke, you name it.
We're probably pursuing something with it,
and we were one of five centres set up by through the Life Sciences Industry Strategy just over a year ago to support
aoy developments in medical imaging and digital pathology with the view that these were some of the low hanging fruit,
why you could see the use of AI and the use of healthcare data for innovation and to drive patient impact.
So as I said, we were set up with a range of aspirations to support companies and academics and progressing
particular use cases of AI in health care and ensuring that we're engaging the NHS workforce.
And how are we doing that in an ethical way that you're including patient consent,
both for retrospective as well as prospective data collection, which some of you may have seen in the Guardian over the weekend.
The idea of anonymized data and can you really anonymize data is one that's close to conversations about having an ally for us at the moment,
how people feel about the use of commercial entities,
engaging with their health datasets and also trying to ensure that we're bringing the patient and
public perspective in which is why we've been working with Michael McKenzie and some of the and.
So we're supporting a range of different projects, and they're sort of maps out along a pipeline of development from areas of clinical unmet need all
the way through to companies with solutions that are looking to test and deploy into the NHS.
And those present different challenges in sense of whether they're being prospectively or retrospectively acquired,
whether there is informed consent around these studies and then the aspects around deployment of air
developed by large entities such as health care in the US and the deployment of those into the NHS,
and also the questions around how we ensure that everybody in the ecosystem is creating value back out of that.
So not only the commercial value proposition, but also societal, academic,
commercial and other forms of value that we're working with both Mike and the team and
some of our external collaborators around how to capture those different times of value.
So those are all projects we are progressing through, the UK says, and I wanted to give a couple of quick example.
So this is one that involves when I was a start-up that spun out of the University of Oxford just over a year ago.
So this was an academic research group that have used data from cardiac CT images and are progressing a new measure for fat attenuation index,
which is a new marker that picks up of those 50 percent of people that go for cardiac CT because they're at risk of cardiovascular disease,
about half the percent y going you fine of that 50 percent,
about 25 percent of those are actually at risk of this new marker has been picked up through looking at the same images you were acquiring already,
and you can detect new risk disease cohorts that you can then pick up and do something with more proactively.
So the group inside the university developed an algorithm for this,
and we're supporting them in scaling that up and gathering more datasets to develop that into a solution could then be deployed into the NHS.
This is another quite different cohort, so we're working with a charity called him a Premier.
Tice's UK hemochromatosis is an incredibly common genetic hereditary disorder, which is involved with presents as iron overload,
but is chronically misdiagnosed with a lack of about 20 to 25 years before people are accurately diagnosed.
The treatment is giving blood,
so it's not of interest to big pharma companies because they're not going to make a Big Bang for their buck out of trying to cure these patients.
But it is an unmet need where the use of imaging can pick up the disease through an MRI scan,
and you can detect the iron levels in the liver and get them treated much sooner.
So we're supporting a company and progressing how you would take that standard of care MRI images and flag up to
patients and clinicians that they are at risk of having excessive iron and then be treated through giving blood.
And these patients. So Kareena is actually the chair of the charity, and she was, as you can see, symptoms at 20 and over 25 years to be diagnosed.
The charity themselves are very interested in directly donating their image
and other patient datasets for research and for commercial research as well.
So talking with them about what it means to be a patient that wants to donate the image records directly for research and commercial use.
Just the other end of the extreme is E stroke suite. So this is deployed in the NHS currently and is a new method for mobile device pick
up detection of patients more rapidly for those at risk of stroke and intervention.
And this is about putting that absolution into the hands of the clinicians to be able to detect to read
the scans remotely and then get the patients that need to be into the appropriate clinical care pathway.
And we've been talking about deploying that into eight new hospitals into London,
and that would generate over 17 million pounds worth of quality adjusted life year benefit in the next three years if that was deployed.
So very significant potential benefits from an app based solution and just a kind of kind of screen scrolling through these.
And then another one is critical care suite. So this is something which is a never even in the NHS.
Nasogastric tubes are placed in order to feed patients who can't otherwise feed themselves.
This tends to be a risky situation in the middle of the night in an eye and he department,
where you've got a junior doc who's not slept for 36 hours and is trying to get this patient fed as quickly as possible.
If they're incorrectly placed, they can end up not in the stomach, but in the lungs or in the chest cavity and feeding him begin.
And you can end up either with severe adverse events or you can end up with a dead patient in order to avoid those arising.
We're working with G to pick up an automation for this process, not to take away the decision from the clinicians, but to flag those.
But there may be a problem. So trying to help pick up those cases where there might be a risk because otherwise
these are picked up as a never event and no significant financial as well,
as well as societal and individual patient impacts for this going awry.
So those are sort of three or four of the projects that we're working on across the piece.
And all of this is underpinned with what we've been doing and beginning with Michael McKenzie around, what does it mean to be using these?
Ethically, particularly around image data, which has a certain sense of can you ever truly anonymize the data sets we're working with?
Are we in effect in a position that you can't work with historic records within the hospitals?
Because can you truly anonymize the data without consent?
Can you be using retrospective data sets and the very different perspectives patients versus the general
public feel about the use of image and other datasets for both academic research and commercial research?
So we're working with both the Ethics Centre as well as Future Care Capital and some of a company called the behavioural
architects to discuss some of the key drivers and leave us for having some of these conversations to bring the patients with us.
And we're hoping that by doing this will have generated not only solutions that can help care in the future,
but will have also supported the generation of imaging and other data resource for future research projects.
And we're keen to kind of pull more people and more groups into there. So if you'd like to come and join and see me, then please do get in touch.